STALLERGENES-GREER
20.11.2023 12:32:26 CET | Business Wire | Press release
Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), announces the publication of results from the Phase 3 POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) study in the New England Journal of Medicine Evidence. The study evaluated the efficacy and safety of PALFORZIA [defatted powder of Arachis hypogaea L., semen (peanuts)] in peanut-allergic children aged 1 to 3 years.
The study met the primary endpoint, with the majority of patients treated with PALFORZIA tolerating at least a 600 mg single dose (1,043 mg cumulative) or a 1,000 mg single dose (2,043 mg cumulative) of peanut protein (73.5% and 68.4%, respectively, compared to 6.3% and 4.2% of patients who received placebo, respectively). In addition, the majority of patients treated with PALFORZIA (61.2% compared with 2.1% of placebo-treated patients) tolerated the highest exit double-blind, placebo-controlled exit food challenge (DBPCFC) dose level of 2,000 mg (4,043 mg cumulative), and this proportion was higher for the youngest age group.
PALFORZIA demonstrated a favorable safety profile. Overall, 84.7% of patients on PALFORZIA and 93.8% of patients on placebo completed the study. There were no PALFORZIA-related serious or severe adverse events, and systemic allergic reactions due to any cause were similar between PALFORZIA and placebo-treated patients (8.2% and 8.3%, respectively). Treatment-related systemic allergic reactions occurred in 2% of PALFORZIA-treated patients and 0% of placebo-treated patients.
A 3.5-fold increase in peanut allergy prevalence has been reported in recent years, with 1 to 2% of children in Western countries affected1. Reactions to peanut are potentially life-threatening, accounting for the majority of deaths related to food allergy2.
“Through the Poseidon study, we have witnessed a significant shift in how peanut allergy can be managed in the youngest patients,” said George du Toit, M.B., B.Ch., Professor of Pediatric Allergy at Evelina London Children’s Hospital, Guy's and St Thomas' NHS Foundation Trust, King’s College London and study investigator in PALFORZIA clinical trials. “These findings highlight the potential benefit of early intervention for peanut-allergic children aged 1 to 3 years, offering a glimpse of hope for a future where we can alleviate the burden of this condition.”
“We are delighted about the results which underscore the clinical significance of PALFORZIA for peanut-allergic toddlers. The results, published in the New England Journal of Medicine Evidence, are truly promising and potentially life-changing for young patients. The recent addition of PALFORZIA, the first standardised treatment for peanut-allergic toddlers, to Stallergenes Greer’s portfolio is testimony to our unwavering commitment to provide patients and the medical community with innovative AIT treatments,” says Amer Jaber, Chief Innovation Officer of Stallergenes Greer.
To read the publication: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300145
ABOUT POSEIDON PHASE 3 STUDY
POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization, clinicaltrials.gov number NCT03736447) is an international, randomized (2:1), double-blind, placebo-controlled Phase 3 study that evaluated the efficacy and safety of PALFORZIA in peanut-allergic children aged 1 to <4 years of age in North America and Europe. The POSEIDON study was completed by Aimmune Therapeutics, part of Nestlé Health Science before Nestlé divested PALFORZIA to Stallergenes Greer in September 2023. Enrollment was based on several entry criteria, including a documented clinical history of peanut allergy, positive skin prick tests and/or elevated blood levels of peanut antibodies, and dose-limiting symptoms after consuming single doses of peanut protein >3 to ≤300 mg in a positive double-blind, placebo-controlled food challenge (DBPCFC). In POSEIDON, patients underwent a dose-escalation period of approximately 22 weeks to reach a dose of 300 mg per day of PALFORZIA or placebo, then continued that dose for approximately six months. At the end of the trial, patients underwent an exit DBPCFC.
ABOUT PALFORZIA
PALFORZIA is a complex biologic drug used with a structured dosing approach that builds on a century of oral immunotherapy (OIT) research. With OIT, the specific allergenic proteins are ingested initially in very small quantities, followed by incrementally increasing amounts, that can result in the ability to mitigate allergic reactions to the allergen over time. PALFORZIA is a rigorously developed, pharmaceutical-grade OIT for peanut allergy with a well-defined allergen profile to assure the consistency of every dose, from 0.5 mg (equivalent to 1/600th of a peanut) to 300 mg.
PALFORZIA is not intended for, and does not provide, immediate relief of allergic symptoms. Therefore, this medicinal product is not to be used for emergency treatment of allergic reactions, including anaphylaxis. Self-injectable adrenaline (epinephrine) must be available to the patient at all times.
PALFORZIA is approved by the U.S. Food and Drug Administration (FDA) by the European Medicine Agency (EMA), by the Medicines and Healthcare products Regulatory Agency (MHRA) in the U.K., and by Swissmedic in Switzerland.
ABOUT STALLERGENES GREER INTERNATIONAL AG
Headquartered in Baar (Switzerland), Stallergenes Greer International AG is a global healthcare company specialising in the diagnosis and treatment of respiratory and food allergies through the research, development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France). For more information, visit www.stallergenesgreer.com
------------------------
- Lange L, Klimek L, Beyer K, et al. White paper on peanut allergy. Part 1: epidemiology, burden of disease, health economic aspects. Allergo j Int 2021;30:261-269. DOi: 10.1007 / s40629-021-00189-z.
- Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191-193.
PALFORZIA: © 2023, Société des Produits Nestlé S.A. or its affiliates
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231120033267/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Rock-It Company Opens New Regional Office in Nashville16.11.2026 17:00:00 CET | Press release
The expansion demonstrates The Rock-It Company’s dedication to the iconic live music market and opens a new centralized hub that connects live events and luxury goods in a fast-growing region. The Rock-It Company, a global leader in live events and luxury goods logistics, announced the opening of a new regional office in Nashville, Tennessee, reinforcing its presence in one of the world's most important live music and cultural markets. The Nashville office brings together the full Rock-It platform with dedicated offices for Rock-It Cargo, Rock-It Sports, CARS by Rock-It and DIETL by Rock-It, serving as a regional hub for the company's broader portfolio of specialty logistics offerings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116286387/en/ The Rock-It Company office in Nashville, Tennessee “Nashville has been a central part of our business for decades, and we see tremendous opportunity to continue building on that f
IQM Supports NVIDIA’s Work to Make Quantum Computers Schedulable in Slurm16.11.2026 17:00:00 CET | Press release
IQM quantum computers already run at leading supercomputing centers, including Oak Ridge National Laboratory (ORNL), VTT Technical Research Centre of Finland, the Leibniz Supercomputing Centre (LRZ) and CINECA, with users reaching them through Slurm. IQM supports NVIDIA’s investment in making quantum processors a schedulable resource in supercomputing centers by integrating IQM quantum computers with Slurm. IQM’s partner MQSC (Munich Quantum Software Company) has demonstrated the MQSC Orchestrator scheduling IQM systems through the new Slurm capability. IQM Quantum Computers (Nasdaq: IQMX), a global leader in superconducting quantum computers, today announced at SC26 in Chicago its support for NVIDIA’s investment in making quantum processing units (QPUs) a schedulable resource in the Slurm workload manager by integrating IQM quantum computers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116814640/en/ NVIDIA is making q
What Our Pupils Reveal: MindMetrix Joins Wyss Geneva to Bring Eye-Based Biofeedback to Mental Health16.11.2026 15:45:00 CET | Press release
We are proud to welcome MindMetrix AG as one of the newest Wyss Geneva ventures. Born out of research at ETH Zurich’s Neural Control of Movement Lab, MindMetrix is a neurotechnology company that reads the brain’s arousal system through the eyes and turns it into live biofeedback, so people can see, and learn to regulate, their own mental state. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116303495/en/ MindMetrix’s myflow platform turns pupil-based measurements into live biofeedback, with each user’s training sessions and progress shown in a dashboard. Image: MindMetrix The mind is still assessed mostly through questionnaires and self-report, with no objective, real-time measure of brain activity. The size of our pupils changes with the brain’s arousal center, a tiny region deep in the brainstem that is otherwise hard to observe without a brain scan. MindMetrix uses pupillometry to read that signal and turn it into live
Factbird Launches Visual Intelligence and Factbird MCP: AI That Sees the Shop Floor and Connects to Any AI Assistant16.11.2026 15:39:00 CET | Press release
Two new AI capabilities, available now. Visual Intelligence turns camera footage into production data. Factbird MCP gives AI assistants direct access to production data in Factbird. Today, Factbird announces the launch of two new AI capabilities. Visual Intelligence uses cameras and AI to measure what sensors and PLCs miss. Factbird MCP lets AI assistants such as Claude, ChatGPT, and Microsoft Copilot work directly with production data in Factbird. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113769016/en/ Factbird Visual Intelligence tracking a bottling line in real time, showing filler and shrink wrapper status, line speed of 72 bottles per minute, and operator activity around the line. (AI-generated illustration) The losses that are hardest to explain happen around the machine. A station waits for material. A manual task runs long on the night shift. Each one costs a few minutes, and over a year they add up to real c
Argenta and Loyal Announce Partnership to Advance LOY-003, Loyal's Lifespan-Extension Candidate for Large-Breed Dogs16.11.2026 15:17:00 CET | Press release
Collaboration brings together Argenta's Molecule to Market capabilities and Loyal’s lifespan extension therapeutics with early development of LOY-003 Argenta, the global contract development, research and manufacturing organization (CDRMO) dedicated exclusively to animal health, and Loyal, the clinical-stage animal health company pioneering the first lifespan extension drugs for dogs, today announced a strategic partnership under which Argenta will support early-stage development of LOY-003, Loyal's investigational candidate for large-breed dog lifespan extension. The collaboration will focus on early development of the drug, with the potential to expand as the program advances. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116891949/en/ Founded by CEO Celine Halioua, Loyal is working to bring the first FDA-approved lifespan extension drugs to market for dogs. The company's pipeline includes three investigational candida
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
